AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9930597 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine (3% PT-IgE at 7 months)
Number of subjects: 189
Study 9930597 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic children (36% PT-IgE after vaccination)
Number of subjects: 189
Study 9930597 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with pertussis (30% PT-IgE)
Number of subjects: 189
Study 9930597 — intervention group
Group type: COMPARATOR
Intervention: Nonatopic children (10% PT-IgE after vaccination)
Number of subjects: 189
Study 8049448 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg IV for days 1-22, then 0.5 mg/kg for days 22-35)
Number of subjects: 147
Study 8049448 — intervention group
Group type: COMPARATOR
Intervention: No methylprednisolone (control group)
Number of subjects: 147
Study 3133251 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified follicle-stimulating hormone (pure-FSH)
Number of subjects: 20
Study 3133251 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 20
Study 3133251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study 11604193 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 200 mg vaginal suppositories three times during 2 days before administering misoprostol.
Number of subjects: 52
Study 11604193 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories.
Number of subjects: 52
Study 31907080 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily lutein supplementation for 12 weeks
Number of subjects: 120
Study 31907080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30199515 — intervention group
Group type: EXPERIMENTAL
Intervention: PC gaming platform (12 weeks)
Number of subjects: 40
Study 30199515 — intervention group
Group type: COMPARATOR
Intervention: Computer mouse (control group)
Number of subjects: 40
Study 26755665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led telephone consultations (2 consultations, 4-6 weeks apart) plus a written summary and a medicines reminder chart.
Number of subjects: 677
Study 26755665 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 677
Study 24866022 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-selenite treatment (1000-μg/2 hours load, followed by 1000-μg/die)
Number of subjects: 40
Study 24866022 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-selenite treatment
Number of subjects: 40
Study 24866022 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 22424877 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmth exposure
Number of subjects: 47
Study 22424877 — intervention group
Group type: COMPARATOR
Intervention: Sucrose taste
Number of subjects: 47
Study 22424877 — intervention group
Group type: COMPARATOR
Intervention: Pacifier suckling
Number of subjects: 47
Study 20339833 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 20339833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18064446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (Nature Made R) given 2 hours before ESWL, and 2 and 8 hours after ESWL (Group B)
Number of subjects: 120
Study 18064446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (Nature Made R) given 2 and 8 hours after ESWL (Group C)
Number of subjects: 120
Study 18064446 — intervention group
Group type: COMPARATOR
Intervention: No antioxidants (Control Group A)
Number of subjects: 120
Study 16055569 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine continuous wound infusion
Number of subjects: 79
Study 16055569 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 79
Study 12658791 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN
Number of subjects: 0
Study 10512925 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR A677V allele in patients with CAS
Number of subjects: 48
Study 10512925 — intervention group
Group type: COMPARATOR
Intervention: Control subjects without CAS
Number of subjects: 48
Study 7574757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (preoperative hyperthermia, irradiation, 5-fluorouracil suppository)
Number of subjects: 31
Study 7574757 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 31
Study 1701742 — intervention group
Group type: EXPERIMENTAL
Intervention: Home assessment
Number of subjects: 50
Study 1701742 — intervention group
Group type: COMPARATOR
Intervention: Clinic assessment
Number of subjects: 50
Study 458602 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen with crystals smaller than 100 mesh (mean equivalent spherical diameter = 67 micron)
Number of subjects: 10
Study 458602 — intervention group
Group type: COMPARATOR
Intervention: Benoxaprofen with crystals larger than 60 mesh (mean equivalent spherical diameter = 640 micron)
Number of subjects: 10
Study 31352906 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol levels (per 10 μg/dl increases)
Number of subjects: 462
Study 31352906 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 2-4 retinol levels (≥ 52.3 μg/dl) compared to quartile 1 (< 52.3 μg/dl)
Number of subjects: 462
Study 31352906 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol levels (per 10 μg/dl increases) in participants with retinol < 68.2 μg/dl
Number of subjects: 462
Study 31352906 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol levels (per 10 μg/dl increases) in participants with retinol ≥ 68.2 μg/dl
Number of subjects: 462
Study 29474547 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use treatment and trauma symptom management
Number of subjects: 7
Study 26669430 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of Ca (2·4 g Aquamin)
Number of subjects: 300
Study 26669430 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of Ca with 3 g of scFOS
Number of subjects: 300
Study 26669430 — intervention group
Group type: COMPARATOR
Intervention: Control (maltodextrin)
Number of subjects: 300
Study 24631278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice, cold water at ∼11°C)
Number of subjects: 26
Study 24631278 — intervention group
Group type: COMPARATOR
Intervention: Control (tepid water at ∼26°C)
Number of subjects: 26
Study 22621166 — intervention group
Group type: EXPERIMENTAL
Intervention: G79 (primer application + heat treatment at 79°C) without aging
Number of subjects: 14
Study 22621166 — intervention group
Group type: COMPARATOR
Intervention: GC (control, without primer)
Number of subjects: 14
Study 22621166 — intervention group
Group type: EXPERIMENTAL
Intervention: G20 (primer application at ambient temperature 20°C)
Number of subjects: 14
Study 22621166 — intervention group
Group type: EXPERIMENTAL
Intervention: G100 (primer application + heat treatment at 100°C)
Number of subjects: 14
Study 22621166 — intervention group
Group type: EXPERIMENTAL
Intervention: G45 (primer application + heat treatment at 45°C)
Number of subjects: 14
Study 22621166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging groups (all experimental groups)
Number of subjects: 14
Study 20954960 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow abdominal breathing combined with EMG biofeedback training
Number of subjects: 22
Study 20954960 — intervention group
Group type: COMPARATOR
Intervention: Slow abdominal breathing
Number of subjects: 22
Study 20954960 — intervention group
Group type: EXPERIMENTAL
Intervention: AB+BF group (slow abdominal breathing + EMG biofeedback)
Number of subjects: 22
Study 20954960 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study 17388962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (group B)
Number of subjects: 40
Study 17388962 — intervention group
Group type: COMPARATOR
Intervention: Diet (group A)
Number of subjects: 40
Study 17388962 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 40
Study 16322134 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (170-425 mg once daily)
Number of subjects: 248
Study 16322134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 16322134 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 248
Study 12224807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional processing of frequency
Number of subjects: 0
Study 12224807 — intervention group
Group type: COMPARATOR
Intervention: Unintentional processing of frequency
Number of subjects: 0
Study 11605079 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine sulfate (10 mg and 20 mg)
Number of subjects: 22
Study 11605079 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion hydrochloride (150 mg and 300 mg)
Number of subjects: 22
Study 11605079 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 9581412 — intervention group
Group type: EXPERIMENTAL
Intervention: Round 2-mm-diameter bar with clips
Number of subjects: 50
Study 9581412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments (Nobel Biocare)
Number of subjects: 50
Study 9581412 — intervention group
Group type: COMPARATOR
Intervention: Both attachment systems
Number of subjects: 50
Study 7921524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17
Study 7921524 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 17
Study 7921524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 3395543 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-arterial technique
Number of subjects: 2
Study 3395543 — intervention group
Group type: COMPARATOR
Intervention: Winnie technique
Number of subjects: 2
Study 4553818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (AMCA, Cyclokapron), 1 g three times a day for five days
Number of subjects: 0
Study 4553818 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31005246 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy (arm B)
Number of subjects: 80
Study 31005246 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesic treatment (arm A)
Number of subjects: 80
Study 28054262 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMT
Number of subjects: 40
Study 28054262 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG
Number of subjects: 40
Study 28054262 — intervention group
Group type: EXPERIMENTAL
Intervention: PCG
Number of subjects: 40
Study 28054262 — intervention group
Group type: COMPARATOR
Intervention: CG
Number of subjects: 40
Study 28054262 — intervention group
Group type: COMPARATOR
Intervention: PG
Number of subjects: 40
Study 25303170 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minutes of self‐selected music (pre‐task music condition)
Number of subjects: 18
Study 25303170 — intervention group
Group type: COMPARATOR
Intervention: 5 minutes of silence (control condition)
Number of subjects: 18
Study 23731284 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD deactivation (Group 1)
Number of subjects: 98
Study 23731284 — intervention group
Group type: COMPARATOR
Intervention: No ICD deactivation with hospice or DNR orders (Group 2)
Number of subjects: 98
Study 23731284 — intervention group
Group type: COMPARATOR
Intervention: No ICD deactivation without hospice or DNR orders (Group 3)
Number of subjects: 98
Study 23731284 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD shocks in the last week before death
Number of subjects: 98
Study 22042959 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship care plan (SCP) reviewed during a 30-minute educational session with a nurse; PCP received the SCP and guideline on follow-up.
Number of subjects: 408
Study 22042959 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge visit with the oncologist (control group).
Number of subjects: 408
Study 19505775 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 14
Study 19505775 — intervention group
Group type: COMPARATOR
Intervention: Incubator Care (IC)
Number of subjects: 14
Study 17011409 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem medoxomil 300 mg twice daily for 7 days
Number of subjects: 1099
Study 17011409 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem medoxomil 300 mg twice daily for 10 days
Number of subjects: 1099
Study 17011409 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 250 mg twice daily for 10 days
Number of subjects: 1099
Study 15301792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free method using polypropylene mesh (Group A)
Number of subjects: 34
Study 15301792 — intervention group
Group type: COMPARATOR
Intervention: Andrews technique (Group B)
Number of subjects: 34
Study 11402108 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIg) 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months
Number of subjects: 55
Study 11402108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11402108 — intervention group
Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIg)
Number of subjects: 55
Study 9167925 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft (Jones) dressing
Number of subjects: 60
Study 9167925 — intervention group
Group type: COMPARATOR
Intervention: Short leg cast
Number of subjects: 60
Study 8461219 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 99
Study 8461219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25 mg twice daily)
Number of subjects: 21
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg twice daily)
Number of subjects: 21
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus Enalapril
Number of subjects: 21
Study 3026294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 21
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 21
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Hydrochlorothiazide plus Enalapril)
Number of subjects: 21
Study 3026294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 21
Study 31750225 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic underlay myringoplasty without gelfoam
Number of subjects: 80
Study 31750225 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic underlay myringoplasty with gelfoam
Number of subjects: 80
Study 29291887 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 7554
Study 29291887 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 7554
Study 24100256 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil target-controlled infusion
Number of subjects: 70
Study 24100256 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine single-dose administration (0.5 μg/kg given 10 minutes before the end of surgery)
Number of subjects: 70
Study 24100256 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine single-dose administration
Number of subjects: 70
Study 24100256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 25272534 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Diltiazem gel applied twice daily for two weeks
Number of subjects: 60
Study 25272534 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Glyceryl TriNitrate applied three times a day for two weeks
Number of subjects: 60
Study 25272534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 60
Study 22865489 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine plus meperidine (RM Group)
Number of subjects: 53
Study 22865489 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine (R Group)
Number of subjects: 53
Study 22865489 — intervention group
Group type: COMPARATOR
Intervention: Saline (C Group)
Number of subjects: 53
Study 20682156 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 5 microg*kg(‐1). min(‐1) (n = 10)
Number of subjects: 20
Study 20682156 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone 0.5 microg*kg(‐1)*min(‐1) (n = 10)
Number of subjects: 20
Study 17414607 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hepatic and regional arterial chemotherapy (PHRAC)
Number of subjects: 222
Study 17414607 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery alone)
Number of subjects: 222
Study 15781429 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO+EZE
Number of subjects: 625
Study 15781429 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO
Number of subjects: 625
Study 15781429 — intervention group
Group type: EXPERIMENTAL
Intervention: EZE
Number of subjects: 625
Study 15781429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 14623690 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse 532-nm Nd:YAG laser treatment
Number of subjects: 7
Study 14623690 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 7
Study 10621853 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin gel
Number of subjects: 10
Study 10621853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10621853 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% isotretinoin gel after placebo
Number of subjects: 10
Study 10621853 — intervention group
Group type: EXPERIMENTAL
Intervention: bcl-2 positivity
Number of subjects: 10
Study 10621853 — intervention group
Group type: EXPERIMENTAL
Intervention: apoptotic bodies
Number of subjects: 10
Study 8961487 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential alternating chemotherapy (Adriamycin/cisplatin and bleomycin/vinblastine; 8.5 +/- 5 cycles)
Number of subjects: 123
Study 8961487 — intervention group
Group type: COMPARATOR
Intervention: Standard PEB chemotherapy (cisplatinum/etoposide/bleomycin; 5.7 +/- 2.1 cycles)
Number of subjects: 123
Study 8961487 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal lymph node dissection (RPLND) after chemotherapy
Number of subjects: 123
Study 1809531 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 basic chemicals (imipramine, norephedrine, nicotine, 8-aminoquinoline) applied via a 24-hour patch
Number of subjects: 16
Study 1809531 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 16
Study 7073415 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (15, 20, and 30 g/day)
Number of subjects: 245
Study 7073415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (2.0 g/day)
Number of subjects: 245
Study 7073415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 7073415 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride
Number of subjects: 245
Study 2867731 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (DFL)
Number of subjects: 43
Study 2867731 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextropropoxyphene napsylate (DPN)
Number of subjects: 43
Study 2867731 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (DFL) and Dextropropoxyphene napsylate (DPN)
Number of subjects: 43
Study 29653915 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF (ready-to-use supplementary food)
Number of subjects: 1805
Study 29653915 — intervention group
Group type: COMPARATOR
Intervention: no-RUSF
Number of subjects: 1805
Study 29653915 — intervention group
Group type: EXPERIMENTAL
Intervention: RUSF
Number of subjects: 1805
Study 27351320 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg daily
Number of subjects: 198
Study 27351320 — intervention group
Group type: COMPARATOR
Intervention: Lactose tablets (Control)
Number of subjects: 198
Study 25063013 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% ethanol locks
Number of subjects: 85
Study 25063013 — intervention group
Group type: COMPARATOR
Intervention: Heparinized saline
Number of subjects: 85
Study 22107266 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal rush immunotherapy using depigmented polymerized allergenic extract of mixed grass pollen
Number of subjects: 195
Study 22107266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 20507672 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban group
Number of subjects: 7049
Study 20507672 — intervention group
Group type: EXPERIMENTAL
Intervention: Migrant group
Number of subjects: 7049
Study 20507672 — intervention group
Group type: COMPARATOR
Intervention: Rural group
Number of subjects: 7049
Study 20507672 — intervention group
Group type: EXPERIMENTAL
Intervention: Western food consumption
Number of subjects: 7049
Study 18285432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-task training for 30 minutes once a week during the three-week training phase
Number of subjects: 5
Study 18285432 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 5
Study 16174117 — intervention group
Group type: COMPARATOR
Intervention: Low-stress group (Group A) with LV-SWS of 92.0 ± 18.0 mmHg/cm2
Number of subjects: 38
Study 16174117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stress group (Group B) with LV-SWS of 134.2 ± 32.3 mmHg/cm2
Number of subjects: 38
Study 11802108 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg)
Number of subjects: 24
Study 10197230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lignocaine 40 mg
Number of subjects: 20
Study 10197230 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lignocaine 160 mg
Number of subjects: 20
Study 10197230 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 10197230 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol pretreatment with lignocaine
Number of subjects: 20
Study 8116726 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 60
Study 8116726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3291558 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dose 197 mg/day)
Number of subjects: 23